Distal Transradial Access in the Anatomical Snuffbox for Interventional Coronary Procedures: Analysis of Access Site Pain and Complications.

INTRODUCTION: A novel arterial access distally on the radial artery through the anatomical snuffbox has been recently described for coronary interventional procedures. However, there is insufficient data comparing the advantages and limitations of distal transradial access (dTRA), conventional transradial access (TRA), and transfemoral access (TFA). The aim of this study was to compare the three access sites regarding local pain and complications during or after coronary interventional procedures. METHODS: This prospective observational single-center study included 211 patients undergoing cardiac catheterization or percutaneous coronary intervention, divided into three groups: dTRA (n=69), TRA (n=71), and TFA (n=71). The access site was chosen at the discretion of three operators. We administered a questionnaire to all patients, addressing local pain or discomfort during or after the procedure and the occurrence of possible complications such as distal pallor, local bleeding, and purple color on the access site. RESULTS: Pain on the access site during the procedure was reported more frequently in the TRA group (dTRA 15.9% vs. TRA 32.4% vs. TFA 15.5%). There were no differences in the occurrence of local pain after the procedure in all three groups (29.6% in the dTRA group, 28.2% in the TRA group, and 26.8% in the TFA group). Pain intensity, when it occurred, was higher in the dTRA group (dTRA 5.8 vs. TRA 4.8 vs. TFA 4.6 on a 1-10 scale), as was its duration (dTRA 13.7 vs. TRA 7.6 vs. TFA 8.2 days). Only two local bleeding events were reported, both in the TFA group. No major complications were recorded. CONCLUSION: The occurrence of local pain on the puncture site after coronary interventional procedures did not differ among the three groups. The dTRA group presented a lower incidence of pain during the procedure when compared to TRA and a lower incidence of purple color when compared to TFA. However, pain intensity and duration were higher in the dTRA group when pain was reported. Using dTRA for coronary procedures is a feasible and safe strategy in selected cases.

Distal transradial access in the anatomical snuffbox for interventional coronary procedures: analysis of access site pain and complications

INTRODUCTION: A novel arterial access distally on the radial artery through the anatomical snuffbox has been recently described for coronary interventional procedures. However, there is insufficient data comparing the advantages and limitations of distal transradial access (dTRA), conventional transradial access (TRA), and transfemoral access (TFA). The aim of this study was to compare the three access sites regarding local pain and complications during or after coronary interventional procedures. METHODS: This prospective observational single-center study included 211 patients undergoing cardiac catheterization or percutaneous coronary intervention, divided into three groups: dTRA (n=69), TRA (n=71), and TFA (n=71). The access site was chosen at the discretion of three operators. We administered a questionnaire to all patients, addressing local pain or discomfort during or after the procedure and the occurrence of possible complications such as distal pallor, local bleeding, and purple color on the access site. RESULTS: Pain on the access site during the procedure was reported more frequently in the TRA group (dTRA 15.9% vs. TRA 32.4% vs. TFA 15.5%). There were no differences in the occurrence of local pain after the procedure in all three groups (29.6% in the dTRA group, 28.2% in the TRA group, and 26.8% in the TFA group). Pain intensity, when it occurred, was higher in the dTRA group (dTRA 5.8 vs. TRA 4.8 vs. TFA 4.6 on a 1-10 scale), as was its duration (dTRA 13.7 vs. TRA 7.6 vs. TFA 8.2 days). Only two local bleeding events were reported, both in the TFA group. No major complications were recorded. CONCLUSION: The occurrence of local pain on the puncture site after coronary interventional procedures did not differ among the three groups. The dTRA group presented a lower incidence of pain during the procedure when compared to TRA and a lower incidence of purple color when compared to TFA. However, pain intensity and duration were higher in the dTRA group when pain was reported. Using dTRA for coronary procedures is a feasible and safe strategy in selected cases.

P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial

Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open-label trial with a blinded outcome assessment designed to compare SAPT versus DAPT in 3,400 ACS patients undergoing PCI with the latest-generation drug-eluting stents (DES). After successful PCI and up to 4 days following hospital admission, patients are randomised to receive SAPT with a potent P2Y12 inhibitor (ticagrelor or prasugrel) or DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. Aspirin is discontinued immediately after randomisation in the SAPT group. The choice between ticagrelor and prasugrel is at the investigator's discretion. The primary hypothesis is that SAPT will be non-inferior to DAPT with respect to the composite endpoint of all-cause mortality, stroke, myocardial infarction or urgent target vessel revascularisation, but superior to DAPT on rates of bleeding defined by Bleeding Academic Research Consortium 2, 3 or 5 criteria. NEOMINDSET is the first study that is specifically designed to test SAPT versus DAPT immediately following PCI with DES in ACS patients. This trial will provide important insights on the efficacy and safety of withdrawing aspirin in the early phase of ACS.

P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.

Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open-label trial with a blinded outcome assessment designed to compare SAPT versus DAPT in 3,400 ACS patients undergoing PCI with the latest-generation drug-eluting stents (DES). After successful PCI and up to 4 days following hospital admission, patients are randomised to receive SAPT with a potent P2Y12 inhibitor (ticagrelor or prasugrel) or DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. Aspirin is discontinued immediately after randomisation in the SAPT group. The choice between ticagrelor and prasugrel is at the investigator's discretion. The primary hypothesis is that SAPT will be non-inferior to DAPT with respect to the composite endpoint of all-cause mortality, stroke, myocardial infarction or urgent target vessel revascularisation, but superior to DAPT on rates of bleeding defined by Bleeding Academic Research Consortium 2, 3 or 5 criteria. NEOMINDSET is the first study that is specifically designed to test SAPT versus DAPT immediately following PCI with DES in ACS patients. This trial will provide important insights on the efficacy and safety of withdrawing aspirin in the early phase of ACS. (ClinicalTrials.gov: NCT04360720).

Perfuração coronária durante intervenção coronária percutânea: descrição de uma técnica de salvamento / Coronary perforation during percutaneous coronary intervention: description of a salvage technique

A perfuração de artéria coronária durante intervenção coronária percutânea é um evento incomum (0,43%), porém potencialmente grave e com elevado risco de tamponamento cardíaco e morte. Perfurações graves exigem implante de stent recoberto, muitas vezes indisponível. Descrevemos uma técnica alternativa e simples de tratamento, que pode ser realizada com uso de politetrafluoretileno de um balão amarrado sobre um stent coronário.

A coronary artery perforation during percutaneous coronary intervention is an uncommon (0.43%) but potentially severe event, with high risk of cardiac tamponade and death. Severe perforations require placing a covered stent, which is often unavailable. We describe an alternative and simple treatment technique, which can be performed using polytetrafluoroethylene from a balloon tied over a coronary stent.

Is Age Associated with Complications of Atrial Fibrillation Catheter Ablation?

Abstract Background Atrial fibrillation (AF) is the most frequent arrhythmia, and its prevalence increases with age. The management of AF in the elderly is challenging, as it is normally associated with comorbidities and frailty. AF catheter ablation (CA) is a safe and superior alternative to antiarrhythmic drugs (AADs) for the maintenance of sinus rhythm. Objectives To evaluate the rate of complications associated with CA for AF across different age groups. Methods A retrospective analysis of 219 patients who underwent CA for AF between 2016 and 2020 were divided into 3 age groups: less than 60 years, 60 to 70 years, and > 70 years. All the included patients underwent radiofrequency ablation using an electroanatomic mapping system. Categorical variables were evaluated with chi-square and Fisher's test, and continuous variables were evaluated by Kruskal-Wallis and post-hoc Tamhane's T2. P values less than 0.05 were considered significant. Results We found an overall total complication rate of 4.6%. The total complication rate was 3.3% in patients < 60 years of age, 5.7% in patients between 60 and 70 years, and 5.2% in patients > 70 years (p = 0.742). No deaths occurred. Conclusion There was no significant difference in the AF CA-related complications when comparing the patients by age group.

Inflammation as a Prognostic Marker in Heart Failure.

BACKGROUND: Heart failure (HF) is a chronic cardiac disease of great importance worldwide and responsible for one-fifth of hospitalizations for cardiovascular disease in Brazil. Pro-inflammatory mediators are involved in the pathophysiology of HF. However, the impact of inflammatory markers on the prognosis of the disease remains uncertain. OBJECTIVE: We aimed to evaluate inflammation as a prognostic marker in chronic HF. METHODS: In this prospective, single-center, observational cohort study conducted from June 2018 through December 2019, we included outpatients with HF from a specialized service of a teaching hospital. Patients with decompensated HF requiring hospitalization in the last 30 days were excluded. At the time of inclusion, serum C-reactive protein (CRP) and albumin were collected and the presence of inflammation was defined as CRP/albumin ≥1.2. Patients with CRP/albumin ratio <1.2 (group A) and CRP/albumin ratio ≥1.2 (group B) were compared. The primary outcome was all-cause mortality. The secondary outcomes were hospitalization for decompensated HF, number of hospitalizations, and number of days of hospitalization in the 12-month follow-up. RESULTS: We included 77 patients, 49 (63.3%) in group A and 28 (3.4%) in group B. Six patients in group A (12.2%) and 10 patients in group B (35.7%) required at least one hospitalization during follow-up (p=0.01). The rate of hospitalizations for decompensated HF for every 100 patients was 16.3 in group A vs 50.0 in group B (p=0.0001) and the average in-hospital length of stay was 12.2 vs 14.2 days per hospitalized patient (p=0.36) in groups A and B, respectively. The mortality rate was 6.1% in group A vs 7.1% in group B (p=0.86). CONCLUSION: In HF outpatients with inflammation evidentiated by the CRP/albumin ratio ≥1.2, the risk of death was similar to patients without inflammation criteria. However, the presence of inflammation led to a three-fold higher risk of hospitalization for HF decompensation.

Successful Left Atrial Appendage Closure with Watchman Device Implantation in Two Patients with Inferior Vena Cava Filters

Percutaneous procedures through femoral access in patients with inferior vena cava (IVC) filter may be at risk of complications. We evaluated the feasibility and safety of left atrial appendage closure (LAAC) through femoral access in patients previously implanted with IVC filter. We described the WatchmanTM device implantation in two patients with formal contraindication for oral anticoagulation. First patient had a GreenfieldTM filter and the second one an OpteaseTM filter, and in this patient an attempt to withdrawal the filter immediately before the LAAC procedure failed. A femoral approach was performed in both patients using a 14 Fr sheath. Before crossing IVC filters, venographies did not detect any thrombus. All steps of IVC filter crossing were performed under fluoroscopic guidance. No immediate or intrahospital complications related to the procedure occurred. Herein, we presented two cases of successful LAAC closure with Watchman device in patients with two different kinds of IVC filters.

Qualidade de vida em pacientes com insuficiência cardíaca: análise de três anos em um serviço especializado

Introdução. A insuficiência cardíaca (IC) apresenta elevada morbimortalidade, além de exercer grande impacto sobre a qualidade de vida (QV). O Minnesota Living with Heart Failure Questionnaire (MLHFQ) é um escore que avalia a QV dos pacientes portadores dessa síndrome, no qual uma maior pontuação reflete uma menor QV. Objetivo. Avaliar a QV dos pacientes com IC após três anos de seguimento em um serviço ambulatorial especializado de um hospital-escola. Métodos. Estudo unicêntrico, descritivo e prospectivo em que se aplicou o MLHFQ, de modo voluntário e sigiloso, a pacientes com IC com fração de ejeção reduzida acompanhados ambulatorialmente na clínica de IC. Foram analisados os resultados dos MLHFQ dos pacientes comparando-se o momento da inclusão no estudo, em 2014, e após o seguimento de três anos, em 2017/18. Resultados. Dos 76 pacientes inicialmente entrevistados, 74 (97,4%) responderam ao questionário e foram incluídos no estudo, em 2014. Após seguimento de três anos, 39,2% (29/74) dos pacientes responderam novamente ao questionário e em 59,8% (45/74) não se pôde aplicar o MLHFQ pela segunda vez (óbitos: 11; perda de acompanhamento no serviço: 21; não localizados: 13). O escore médio obtido pelo MLHFQ foi de 40,3 ± 21 pontos no momento da inclusão e 31,6 ± 23 pontos após três anos de acompanhamento no serviço (p=0,001). Conclusão. Observou-se baixa QV em pacientes com IC incluídos no estudo, havendo melhora significativa após três anos de acompanhamento no serviço especializado. As clínicas de IC podem aumentar expressivamente a QV dos pacientes portadores de IC, proporcionando potencial benefício prognóstico.

Background. Heart failure (HF) presents high morbidity and mortality, besides having great impact on quality of life (QoL). The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a score that assesses the QoL of patients with this syndrome, in which the higher scores indicates lower QoL. Objective. To analyze the QoL of HF patients after three years of follow-up at the specialized outpatient service of a teaching hospital. Methods. Unicentric, descriptive, prospective study that voluntarily and confidentially applied MLHFQ in patients with HF with reduced ejection fraction followed at the HF clinic. The results of the patients MLHFQ compared at the time of inclusion in the study in 2014 and after the three-year follow-up in 2017/18 were analyzed. Results. Of 76 interviewed patients, 74 (97.4%) answered the questionnaire and were included in the study in 2014. After three years, 39.2% (29/74) answered the questionnaire again and in 59.8% (45/74) cannot apply MLHFQ a second time (deaths: 11; loss of follow-up at the service: 21; not found: 13). The mean score reached by the MLHFQ was 40.3 ± 21 points after inclusion and 31.6 ± 23 points after three years of follow-up at the service (p=0.001). Conclusion. We observed low QoL in the patients with HF included on this study, providing improvement of QoL after three years of follow-up at the specialized service. The HF clinics may significantly increase the QoL of HF patients, providing potential prognostic benefit.

Introducción. La insuficiencia cardíaca (IC) tiene una alta morbilidad y mortalidad, además de tener un gran impacto en la calidad de vida (CV). El cuestionario Minnesota Living with Heart Failure Questionnaire (MLHFQ) es un score de puntos que evalúa la CV de los pacientes con este síndrome, en la que una puntuación más alta refleja una menor CV. Objetivo. Evaluar la CV de pacientes con IC tras tres años de seguimiento en un servicio ambulatorio especializado de un hospital universitario. Métodos. Estudio unicéntrico, descriptivo y prospectivo en el que se aplicó el MLHFQ, de forma voluntaria y confidencial, a pacientes con IC con fracción de eyección reducida seguidos de forma ambulatoria en la clínica de IC. Los resultados del MLHFQ de los pacientes se analizaron comparando el tiempo de inclusión en el estudio, en 2014, y después de los tres años de seguimiento, en 2017/18. Resultados. De los 76 pacientes entrevistados inicialmente, 74 (97,4%) respondieron el cuestionario y fueron incluidos en el estudio en 2014. Después de un seguimiento de tres años, el 39,2% (29/74) de los pacientes respondieron el cuestionario nuevamente y en el 59,8% (45/74) no se pudo aplicar el MLHFQ por segunda vez (muertes: 11; pérdida de seguimiento en el servicio: 21; no localizado: 13). La puntuación media obtenida por el MLHFQ fue de 40,3 ± 21 puntos en el momento de la inclusión y de 31,6 ± 23 puntos tras tres años de seguimiento en el servicio (p=0,001). Conclusión. Se observó baja CV en los pacientes con IC incluidos en el estudio, con mejoría significativa a los tres años de seguimiento en el servicio especializado. Las clínicas de IC pueden aumentar significativamente la CV de los pacientes con IC, proporcionando un beneficio pronóstico potencial.

Safety analysis of sacubitril/valsartan in patients with heart failure in Vitória, Espírito Santo

Background: Sacubitril/valsartan has proven its efficacy to reduce cardiovascular mortality, all-cause mortality and sudden death in heart failure with reduced ejection fraction (HFrEF). Thus, it becomes important to evaluate the safety profile of the medication in clinical practice. Objectives: This study aimed to assess safety outcomes on the use of sacubitril/valsartan in patients with HFrEF attended in a Brazilian specialized service. Methods: Prospective observational study that included patients with HFrEF from a specialized ambulatory service, in functional class II-IV, initiated on sacubitril/valsartan as per clinical indication, with a four-month follow-up. Primary outcomes were the occurrence of symptomatic arterial hypotension, hyperkalemia and reduction of renal function. Serum potassium values, blood pressure and creatinine clearance were analyzed at inclusion and at the end of follow-up. A 5% significance level was considered for comparisons. Results: Twenty-six patients were analyzed, 57.7% male, mean age 57.8 ± 10 years, average left ventricle ejection fraction 29.9 ± 7.7%. Symptomatic hypotension occurred in 53.8%, hyperkalemia in 19.2% and reduction of renal function in 6.7%. There was significant difference from initial to final systolic (122 ± 24mmHg versus 109 ± 15mmHg; p=0.024) and diastolic (76 ± 18mmHg versus 66 ± 12mmHg; p=0.022) blood pressure, but no difference in serum potassium (4.8 ± 0.4mEq/L versus 5.0 ± 0.3mEq/L; p=0.07) and creatinine clearance (65 ± 23mL/min/1.73m² versus 66 ± 29mL/min/1.73m²; p=0.89). Conclusions: Symptomatic hypotension was the most frequent side-effect of sacubitril/valsartan. Reduction of blood pressure was observed at the end of follow-up, but no reduction of renal function or significant increase of serum potassium.

Comparison of high-power short-duration (HPSD) ablation of atrial fibrillation using a contact force-sensing catheter and conventional technique: Initial results.

INTRODUCTION: Atrial fibrillation (AFib) ablation is alternative treatment to drugs. Literature suggests that use of contact force (CF) catheter with higher power for short periods is effective and safe. METHODS/RESULTS: Retrospectively analyzed 76 patients undergoing the first ablation. Third five patients-group A: 27 (77%) paroxysmal AFib (PAFib) and 8 (23%) persistent AFib (PersAFib) who underwent ablation at the power of 30 W-17 mL/minute flow with a CF of 10-30 g for 30 seconds. Fourty one patients-group B: 28 (68.3%) PAFib and 13 (31.70%) PersAFib underwent ablation using 45 W on posterior wall with CF of 8/15 g, as well as 50-W anterior wall with CF of 10/20 g-35 mL/minute flow for 6 seconds. Pulmonary vein isolation in both groups and ablated. For patients not in the sinus, we performed cardioversion before ablation. No complications. Group A: Left atrial time 110 ± 29 minutes, total 148 ± 33.6 minutes, radiofrequency time (RF) 4558 ± 1998 seconds, X-ray 8.5 ± 3.5 minutes, and elevation of esophageal temperature (ET) in 26 (74.3%). group B: Left atrial time 70.7 ± 18.5 minutes ( P < .00001), total 106 ± 23 minutes ( P < .00001), RF 1909 ± 675.8 seconds ( P < .00001), X-ray 8.8 ± 6.6 minutes ( P = .221) and elevation of ET in 21 (51.20% - P = .0578). In 6 and 12 months follow-up, we had 9 (25.71%) and 11 (31.42%) recurrences in group A and 5 (12.19%) and 7 (17.07%) in group B ( P = .231 at 6 and P = .14 at 12 months), respectively. CONCLUSIONS: HPSD was safe, useful, and efficient compared with CT, and reduced procedural time and total RF time. HPSD may reduce esophageal injury because of lower heating rate and it may reduce the recurrence of atrial tachyarrythmias.

Hemoglobina e sódio séricos:: marcadores prognósticos precoces na insuficiência cardíaca descompensada

Introdução. A insuficiência cardíaca (IC) descompensada apresenta elevada morbimortalidade. Marcadores prognósticos clínicos e laboratoriais foram identificados, porém a influência precoce da hemoglobina (Hb) e do sódio (Na) séricos é pouco conhecida. Este estudo teve como objetivo avaliar as características clínicas e desfechos em pacientes internados por IC descompensada, conforme dosagem sérica de Hb e Na nas primeiras 24 horas. Material e métodos. Estudo prospectivo observacional que avaliou pacientes adultos internados por IC descompensada acompanhados por até 30 dias após a alta. Os grupos analisados foram: Hb e Na iniciais normais (grupo 1), Hb inicial < 10,0 mg/dl (grupo 2), Na inicial < 135 mEq/l (grupo 3), ou ambas as alterações (grupo 4). O desfecho primário avaliado foi óbito hospitalar ou até 30 dias após a alta. Resultados. Da amostra total de 40 pacientes, 37,5% eram do grupo 1, 35,0% do grupo 2, 7,5% do grupo 3 e 20,0% do grupo 4. A média de idade nos grupos foi de 67,2 ±15 vs 66,4 ±13 vs 59,0 ±11 vs 55,7 ±14 anos (p=0,08). Eram do sexo masculino 60,0%, 35,7%, 100% e 62,5% (p=0,08). Os desfechos observados para cada grupo foram, respectivamente, mortalidade de 6,7% vs 21,4% vs 0% vs 37,5% (p=0,007), reinternação em 30 dias 6,7% vs 28,6% vs 0% vs 12,5% (p=0,12), insuficiência renal aguda 20,0% vs 42,8% vs 33,3% vs 25,0% (p=0,04), necessidade de ventilação mecânica invasiva 13,3% vs 7,1% vs 0% vs 0% (p=0,41) e tempo de internação 16 ±10 vs 17 ±12 vs 24 ±11 vs 33 ±19 dias (p=0,03). Conclusões. Nos pacientes com IC descompensada, Hb < 10 mg/dl nas primeiras 24 horas da internação associou-se à ocorrência de insuficiência renal aguda. A combinação de Hb < 10 mg/dl e Na < 135 mEq/l associou-se a maior mortalidade hospitalar e a aumento do tempo de internação.

Background. Acute decompensated heart failure (HF) has high morbidity and mortality. Clinical and laboratory prognostic markers have been identified, although the early influence of serum hemoglobin (Hb) and sodium (Na) is not precisely known. This study aimed to assess the clinical features and outcomes in patients with decompensated HF, according to serum dosage of Hb and Na within the first 24 hours of admission. Material and methods. Prospective observational study that included hospitalized patients with decompensated HF followed for up to 30 days after discharge. Groups were analyzed as follows: normal Hb and Na (group 1), initial Hb < 10.0 mg/dl (group 2), initial Na < 135 mEq/l (group 3), or both alterations (group 4). The primary outcome was in-hospital or 30-days death. Results. From the total 40 patients sample, 37.5% were in group 1, 35.0% group 2, 7.5% group 3, and 20.0% group 4. Average age was 67.2 ±15 vs 66.4 ±13 vs 59.0 ±11 vs 55.7 ±14 (p=0.08). Male subjects were 60.0%, 35.7%, 100% and 62.5% (p=0.08). Outcomes for each respective group were: mortality 6.7% vs 21.4% vs 0% vs 37.5% (p=0.007), 30-days re-admission 6.7% vs 28.6% vs 0% vs 12.5% (p=0.12), acute renal failure 20.0% vs 42.8% vs 33.3% vs 25.0% (p=0.04), invasive mechanical ventilation 13.3% vs 7.1% vs 0% vs 0% (p=0.41), and length of hospitalization 16 ±10 vs 17 ±12 vs 24 ±11 vs 33 ±19 days (p=0.03). Conclusions. In patients with acute decompensated HF, Hb < 10 mg/dl within the first 24 hours of admission was associated to the occurrence of acute renal failure. The combination of Hb < 10 mg/dl and was associated to higher mortality and higher length of hospitalization.

Hemoglobina y sodio séricos:: marcadores pronósticos precoces en la insuficiencia cardíaca descompensada

Introducción. La insuficiencia cardíaca (IC) descompensada presenta una elevada morbimortalidad. Si bien los marcadores pronósticos clínicos y de laboratorio se han identificados, la influencia precoz de la hemoglobina (Hb) y del sodio (Na) séricos es poco conocida. Este estudio tuvo como objetivo evaluar las características clínicas y resultados en pacientes internados por IC descompensada, conforme a la dosificación sérica de Hb y Na en las primeras 24 horas. Material y métodos. Estudio prospectivo observacional que evaluó pacientes adultos internados por IC descompensada seguidos por hasta 30 días después del alta hospitalaria. Los grupos analizados fueron: Hb y Na iniciales normales (grupo 1), Hb inicial < 10,0 mg/dl (grupo 2), Na inicial < 135 mEq/l (grupo 3), o ambas alteraciones (grupo 4). El resultado primario evaluado fue muerte hospitalaria hasta 30 días después del alta. Resultados. De la muestra total de 40 pacientes, el 37,5% eran del grupo 1, el 35,0% del grupo 2, el 7,5% del grupo 3 y el 20,0% del grupo 4. La media de edad en los grupos fue 67,2 ±15 vs 66,4 ±13 vs 59,0 ±11 vs 55,7 ±14 (p=0,08). Eran del sexo masculino 60,0%, 35,7%, 100% y 62,5% años (p=0,08). Los resultados observados para cada grupo fueron, respectivamente, mortalidad de 6,7% vs 21,4% vs 0% vs 37,5% (p=0,007), readmisión en 30 días: 6,7% vs 28,6% vs 0% vs 12,5% (p=0,12), insuficiencia renal aguda: 20,0% vs 42,8% vs 33,3% vs 25,0% (p=0,04), necesidad de ventilación mecánica invasiva: 13,3% vs 7,1% vs 0% vs 0% (p=0,41) y tiempo de internación: 16±10 vs 17±12 vs 24±11 vs 33±19 días (p=0,03). Conclusiones. En los pacientes con IC descompensada, Hb <10 mg/dl en las primeras 24 horas de la internación se ha asociado a la aparición de insuficiencia renal aguda. La combinación de Hb <10 mg/dl y Na <135 mEq/l se ha asociado a mortalidad más alta y a tiempo de internación más prolongado.

Insuficiência cardíaca na população geriátrica: dados de um registro unicêntrico / Heart failure in the older population: data from a single-center registry

OBJETIVO: Analisar o perfil e o seguimento clínico de pacientes com insuficiência cardíaca. MÉTODOS: Estudo prospectivo observacional de pacientes com insuficiência cardíaca, que comparou a população geriátrica (≥ 65 anos) com o restante da amostra (18 a 64 anos). Todos eram acompanhados ambulatorialmente em clínica especializada de um hospital-escola e foram incluídos consecutivamente entre abril e novembro de 2013, tendo sido acompanhados por 3 anos ou óbito. RESULTADOS: Da amostra total de 100 pacientes, 56% eram idosos. Na comparação entre idosos (média de 74±7 anos) e não idosos (média de 52±8 anos), houve diferença significativa quanto a peso corporal (72,6±16 kg vs. 80,8±19kg; p=0,02), índice de massa corporal (28,6±5,7kg/m2 vs. 32,6±5,9kg/m2; p=0,001), fibrilação atrial (35,7% vs. 11,3%; p=0,005) e doença renal crônica (28,5% vs. 13,6%; p=0,04). A prescrição de betabloqueadores e de inibidores da enzima conversora de angiotensina ou bloqueadores do receptor de angiotensina não diferiu entre os grupos, e nem os dados ecocardiográficos e a ocorrência de desfechos no seguimento clínico. CONCLUSÃO: Idosos foram a maioria dentre pacientes com insuficiência cardíaca e apresentaram maior prevalência de doença renal crônica e fibrilação atrial, além de menores peso e índice de massa corporal. Tais diferenças não resultaram em maior incidência de desfechos adversos na evolução de médio prazo. (AU)

OBJECTIVE: To assess the clinical profile and follow-up of patients with heart failure. METHODS: This is a prospective, observational study that compared the geriatric population (≥ 65 years old) with the remaining portion of the sample (18 to 64 years old). All of them were assisted in a specialized outpatient clinic of a university hospital, and were included consecutively from April to November 2013, being followed for three years or until death. RESULTS: From the sample of 100 patients, 56% were older people. In the comparison between older people (average 74 ± 7 years old) and non-older people (average 52 ± 8 years old), a significant difference was found for body weight (72.6 ± 16Kg vs. 80.8 ± 19Kg, p=0.02), body mass index (28.6 ± 5.7Kg/m2 vs. 32.6 ± 5.9 Kg/m2, p=0.001), atrial fibrillation (35.7% vs. 11.3%, p=0.005), and chronic kidney disease (28.5% vs. 13.6%, p=0.04). The prescription of beta-blockers and angiotensin converting enzyme inhibitors, or angiotensin receptor blockers did not differ between the groups, neither did the echocardiographic values and the occurrence of outcomes at clinical follow-up. CONCLUSION: Older people were the majority among patients with heart failure, and presented a higher prevalence of chronic kidney disease and atrial fibrillation, and lower body weight and body mass index. Those differences did not result in greater incidence of adverse outcomes at mid-term follow-up. (AU)

Acute myocardial infarction and primary percutaneous coronary intervention at night time / Infarto agudo do miocárdio e intervenção coronariana percutânea primária no período noturno

Background: Primary percutaneous coronary intervention is the preferred treatment in ST-elevation myocardial infarction. At night period, the delay until performing primary percutaneous coronary intervention may be determinant to prognosis worsening. Objective: To analyze the results of primary percutaneous coronary intervention performed at day and night periods. Methods: Cohort study that included patients admitted with ST-elevation myocardial infarction who underwent primary percutaneous coronary intervention from December 2013 until December 2016 in a ST-elevation myocardial infarction reference hospital of a metropolitan region in Brazil, followed from admission to hospital discharge or death, compared according to time of primary percutaneous coronary intervention (night or day). Statistical analysis comprehended the Chi-square test, the Fisher test, the Student's t-test and the analysis of variance, with significance level of 5%. Results: 446 patients were submitted to primary percutaneous coronary intervention, 159 (35.6%) at night time and 287 (64.4%) at day time. No differences were found between the two groups concerning clinical baseline characteristics. Door-to-balloon time (101 ± 81 minutes vs. 99 ± 78 minutes; p = 0,59) and onset-to-ballon time (294 ± 158 minutes vs. 278 ± 174 minutes; p = 0,32) did not differ between the groups. The incidence of combined major adverse cardiac events (15.1% vs. 14.3%; p = 0,58) and in-hospital mortality (9.4% vs. 8.0%; p = 0,61) were similar between the groups, as well as length of hospital stay (6.0 ± 4 days vs. 4.9 ± 4 days; p = 0,91). Conclusion: Primary percutaneous coronary intervention at night time showed similar results as the procedure performed at day time, without significant increase of in-hospital adverse events, length of stay or mortality

Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers

SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients - 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.

RESUMO OBJETIVO Este estudo teve como objetivo analisar o papel dos betabloqueadores na prevenção da cardiotoxicidade induzida pelas antraciclinas em adultos. MÉTODOS Foi realizada uma revisão sistemática em bases de dados eletrônicos, incluindo os estudos relevantes que analisaram fármacos betabloqueadores como agentes cardioprotetores antes do início do uso de antraciclinas por pacientes oncológicos adultos. RESULTADOS Após aplicação dos critérios de elegibilidade e seleção, foram obtidos oito artigos considerados de boa qualidade, que se adequavam à temática proposta, sendo todos ensaios clínicos, quatro placebo-controlados, totalizando 655 pacientes incluídos. Destes, 281 (42,9%) fizeram uso de algum betabloqueador como intervenção, sendo o carvedilol o mais utilizado (167 pacientes - 25,5%). Seis estudos foram considerados positivos quanto à cardioproteção exercida pelos betabloqueadores, porém apenas quatro demonstraram diferença na fração de ejeção do ventrículo esquerdo após a quimioterapia nos grupos que usaram betabloqueadores em relação aos grupos controle. O carvedilol e o nebivolol, mas não o metoprolol, tiveram resultados positivos quanto à cardioproteção. Outros betabloqueadores não foram avaliados nos estudos incluídos. CONCLUSÕES Apesar de haver um potencial efeito cardioprotetor dos betabloqueadores, conforme demonstrado em ensaios clínicos pequenos e unicêntricos, sua utilização rotineira na prevenção da cardiotoxicidade associada às antraciclinas requer maiores comprovações científicas.

Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.

OBJECTIVES: This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS: A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS: After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients - 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS: Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.

Acompanhamento de Gestante Portadora de Síndrome de Marfan com Tubo Valvado Metálico Aórtico / Management of Pregnant Woman with Marfan Syndrome and Mechanical Aortic Valved Conduit

Relata-se o acompanhamento de paciente gestante, 29 anos, primigesta, portadora da Síndrome de Marfan e tubo valvado metálico aórtico encaminhada ao cardiologista com sete semanas de gestação.Ao ecodopplercardiograma apresentava diâmetro da raiz da aorta de 35 mm, tubo valvado e prótese aórtica metálica normofuncionante. Realizou acompanhamento cardiológico especializado desde então. Na 38a semana de gestação foi submetida ao parto cesariana com anestesia geral, profilaxia de endocardite infecciosa, monitorização cardíaca no centro cirúrgico e pós-operatório na unidade coronariana por 24 horas. Os períodos gestacional e puerpério transcorreram sem eventos hemorrágicos. O acompanhamento clínico e obstétrico de gestantes com Síndrome de Marfan é desafiador, e a condição de prótese valvar mecânica previamente implantada aumenta o risco destas paciente